Thursday, February 23, 2017
09:00 EST Thursday, February 23, 2017
VICTORIA, Feb. 23, 2017 /CNW/ – Emerald Health Therapeutics Inc. (TSXV: EMH) (“Emerald” or the “Company”) is pleased to announce that it has been notified by the TSX Venture Exchange (“TSXV”) that it achieved a ranking of 3rd Place in the Clean Technology & Life Science sector of the 2017 TSX Venture 50®.
“Emerald is thrilled to be part of such an accomplished group of companies, and recognized for its achievements in 2016. While last year was one of transformation for the whole industry, we expect 2017 to be a year of considerable progress for Emerald as we embark on a series of aggressive growth initiatives (see corporate update here). We would like to thank our staff and shareholders for continued support and belief in the future of Emerald,” stated Avtar Dhillon, MD, Executive Chairman.
The 2017 TSX Venture 50® is a ranking of the top performers listed on the TSXV, divided into five industry sectors. The companies are selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume. The TSXV has created a video profile on Emerald, which will be distributed on February 23, 2017, along with the official announcement of the winners.
Join us on our journey of enhancing health through cannabis science.
For more information, explore our website and investor presentation here.
Emerald Health Therapeutics Inc.
Emerald Health Therapeutics, Inc. operates primarily through Emerald Health Botanicals Inc. (“Botanicals”), a wholly owned subsidiary of the Company and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”). Botanicals is authorized to cultivate and sell both dried medical cannabis flowers and medical cannabis oils in Canada. Botanicals currently operates an indoor cultivation facility in Victoria, British Columbia, and plans to construct a much larger purpose built hybrid greenhouse facility on 32 acres in metro Vancouver. Botanicals prides itself on being one of Canada’s most medically focused licensed producers and on having one of the industry’s most qualified management teams with respect to pharmaceutical drug discovery, development and distribution. Botanicals intends to capture unique niches in both the medical and future adult use cannabis markets through its proprietary strains, defensible intellectual property, and superb client experience.
“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
SOURCE Emerald Health Therapeutics, Inc.
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/February2017/23/c4209.html
For further information: Sandy Pratt, CFO, 250-818-9838, email@example.com